Although this drug was not tested on ALL cells grown with stroma, it suggests that treatment of BCP ALL with other inhibitors that efficiently target more than one upstream source of Erk1/2 activation may be more useful than the use of inhibitors that only target Mek1/2. Here, MAP2K1 is linked to acute lymphoblastic leukemia.